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a b s t r a c t
Virus-like particles (VLPs) are a promising vaccine platform due to the safety and efﬁciency. However,
it is still unclear whether polyomavirus-based VLPs are useful for this purpose. Here, we attempted
to evaluate the potential of polyomavirus VLPs for the antiviral vaccine using simian virus 40 (SV40). We
constructed chimeric SV40-VLPs carrying an HLA-A⁎02:01-restricted, cytotoxic T lymphocyte (CTL)
epitope derived from inﬂuenza A virus. HLA-A⁎02:01-transgenic mice were then immunized with the
chimeric SV40-VLPs. The chimeric SV40-VLPs effectively induced inﬂuenza-speciﬁc CTLs and hetero-
subtypic protection against inﬂuenza A viruses without the need of adjuvants. Because DNase I treatment
of the chimeric SV40-VLPs did not disrupt CTL induction, the intrinsic adjuvant property may not result
from DNA contaminants in the VLP preparation. In addition, immunization with the chimeric SV40-VLPs
generated long-lasting memory CTLs. We here propose that the chimeric SV40-VLPs harboring an
epitope may be a promising CTL-based vaccine platform with self-adjuvant properties.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Vaccination has signiﬁcantly contributed to human health in
the prevention and the control of various infectious diseases.
However, there are still numerous challenges for making effective
vaccines against a number of critical human pathogens such as
HIV, HCV, and Mycobacterium tuberculosis (Houghton and
Abrignani, 2005; McMichael et al., 2010; Skeiky and Sadoff,
2006). Most of these pathogens appear to cause persistent and
latent infections. In order to develop successful vaccines against
such diseases, it is essential for the vaccine not only to induce
humoral immunity involving neutralizing antibodies but also to
generate cellular immunity, in particular cytotoxic T lymphocytes
(CTLs) (Koup and Douek, 2011). To eliminate virus-infected cells or
tumor cells, CTLs are more essential than neutralizing antibodies.
Because viruses offer dramatic effectiveness to elicit both strong
humoral and cellular immune responses, many scientists have
attempted to use them in the attenuated form as a vaccine carrier
for the delivery of foreign epitopes as well as a direct immunogen (Liu,
2010; Shiver and Emini, 2004; Sutter and Moss, 1992). However, they
have a variety of potential problems such as reversed virulence and
unwanted inﬂammatory responses. By contrast, subunit vaccines
composed of antigenic proteins or peptides are relatively safe. At the
same time, we know that they generally fail to stimulate protective
cellular immunity. Due to the poor immunogenicity, they should often
contain adjuvants for the enhancement of immune responses. A
variety of adjuvants have been developed for experiments, but few
adjuvants have been licensed for human use due to the risk of side
effects. Furthermore, the widely used adjuvants for humans, alum
(Marrack et al., 2009) and the oil-based formulation MF59 (O'Hagan
et al., 2012) are useful for the augmentation of antibody responses, but
not for cellular immune responses. Therefore, it is necessary to
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/yviro
Virology
0042-6822/$ - see front matter & 2013 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.virol.2013.10.010
n Corresponding author.
nn Corresponding author. Tel.: þ81 49 276 1438; fax: þ81 49 295 9107.
E-mail addresses: handa.h.aa@m.titech.ac.jp (H. Handa),
mmatsui@saitama-med.ac.jp (M. Matsui).
Virology 448 (2014) 159–167
develop a new vaccine platform that is safe and highly effective for the
induction of strong cellular immunity without the need of adjuvants.
Virus-like particles (VLPs) are comprised of multiple copies of viral
surface structural proteins such as the capsid or envelope without
including viral genomes. Since VLPs retain the efﬁcient entry activity
of the virus into host cells without replication, they are considered to
be a much safer alternative than attenuated viruses as an efﬁcient
vaccine platform in the antigen delivery system (Roy and Noad, 2008).
A variety of VLPs have been constructed from many different viruses
(Roy and Noad, 2008), and it was demonstrated that they could
induce neutralizing antibodies (Buonaguro et al., 2002; Herbst-
Kralovetz et al., 2010; Kang et al., 2009). Some of these VLPs were
shown to be a highly immunogenic antigen carrier to elicit CTLs
against inserted foreign antigens (Ding et al., 2009; Lacasse et al.,
2008; Mazeike et al., 2012). It is considered that VLPs are taken up
and cross-presented to T cells by professional antigen presenting cells
(APCs) such as dendritic cells (DCs) (Win et al., 2011). Although
several VLPs were reported to require the co-administration of
adjuvants (Qian et al., 2006; Storni et al., 2004; Young et al., 2006)
for the induction of CTLs, many kinds of VLPs could induce potent
cell-mediated immune responses evenwithout adjuvants (Buonaguro
et al., 2002; Lacasse et al., 2008). However, the adjuvant-like role of
viral structural proteins is poorly understood.
Both papillomavirus and polyomavirus are non-enveloped DNA
viruses, and their capsids are similarly formed by 72 pentameric
capsomers composed of the major capsid proteins, L1 and VP1,
respectively, which are arranged on a skewed icosahedral lattice.
Papillomavirus L1-based VLPs are considered to be one of the most
promising VLPs for a vaccination vehicle because a number of
experiments have proven that they could induce potent cellular
immune responses as well as humoral immunity even in the
absence of adjuvants (Greenstone et al., 1998; Lenz et al., 2001;
Pejawar-Gaddy et al., 2010). Chimeric papillomavirus VLPs
incorporating a foreign epitope effectively induced epitope-
speciﬁc CTLs and protected mice from tumor formation without
the addition of adjuvants (Greenstone et al., 1998; Liu et al., 2000;
Pejawar-Gaddy et al., 2010; Sadeyen et al., 2003). Human papillo-
mavirus VLPs are already available as a prophylactic subunit vaccine
against cervical cancers (Campo and Roden, 2010). Despite the
morphological similarity, however, it is still unclear whether poly-
omavirus VP1-based VLPs are able to evolve into a self-adjuvanting
vaccine platform that provides strong cellular immune responses. It
was shown that hamster (Mazeike et al., 2012) and murine
(Tegerstedt et al., 2005) polyomavirus chimeric VLPs carrying
foreign epitopes could induce epitope-speciﬁc CTLs and reject
epitope-expressing tumors in the absence of adjuvants. By contrast,
other groups reported that human (Goldmann et al., 1999) and
murine (Eriksson et al., 2011) polyomavirus chimeric VLPs failed to
stimulate immune responses and protect against outgrowth of an
epitope-expressing tumor unless administrated with adjuvants. In
addition, although papillomavirus VLPs were capable of inducing
phenotypic and functional maturation of DCs (Lenz et al., 2001),
human (Lenz et al., 2001) and murine (Boura et al., 2005; Tegerstedt
et al., 2007) polyomavirus VLPs could not activate DCs in vitro at all,
suggesting that polyomavirus VLPs may not possess self-adjuvant
properties.
In the current study, we evaluated the potential of polyomavirus
VLPs for the antigen delivery system using simian virus 40 (SV40),
which belongs to the Polyomaviridae family. We have previously
developed the method to prepare SV40 VP1-based VLPs using the
baculovirus expression system (Ishizu et al., 2001; Kawano et al., 2013;
Kosukegawa et al., 1996), and found that there were two loops of VP1,
called the DE and HI loops that could accommodate a foreign peptide
on the surface of VLPs without disrupting the assembly of VLPs
(Kawano et al., 2013; Takahashi et al., 2008). Here, we constructed
SV40-VP1 with an HLA-A⁎02:01-restricted CTL epitope corresponding
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Fig. 1. Intracellular IFN-γ staining of FMP 58-66-speciﬁc CD8þ T cells in HHD mice immunized with the chimeric SV40-VLPs. HHD mice were immunized once with either
FMP-DE-VLPs or FMP-HI-VLPs without adjuvants via various immunization routs including s.c., i.m., i.p., and i.n. administrations. After one week, splenic lymphocytes were
prepared, and stimulated with (þ) or without () FMP 58-66 for 5 h. (A) Cells were then stained for their surface expression of CD8 (x axis) and their intracellular expression
of IFN-γ (y axis). The numbers shown indicate the percentages of intracellular IFN-γ cells within CD8þ T cells. The data are representative of two independent experiments.
At least three mice per group were used in each experiment. (B) The data indicate the percentages of intracellular IFN-γ cells within CD8þ T cells in mice immunized once
with either the chimeric SV40-VLPs via various immunization routs or the FMP 58-66 peptide plus IFA via the s.c. route. Each symbol represents an individual mouse.
Horizontal bars represent the mean. One-way ANOVA was performed for comparison of data. n, Po0.05; NS, not signiﬁcant.
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to the inﬂuenza A virus matrix peptide 58-66 (FMP 58-66) (Gotch
et al., 1987) inserted into the DE loop or the HI loop. We then
investigated whether the chimeric SV40-VP1-based VLPs effectively
induced protective cellular immunity in HLA-A⁎02:01 transgenic mice
without the need of adjuvants, and attempted to demonstrate the
presence of self-adjuvant properties in the chimeric SV40-VLPs.
Results
Induction of FMP-speciﬁc IFN-γ-producing CD8þ T cells in mice
immunized with the chimeric SV40-VLPs
To investigate whether SV40-VLPs carrying the FMP 58-66 epitope
could elicit FMP-speciﬁc CTLs, HHD mice were immunized once with
either FMP-DE-VLPs, FMP-HI-VLPs or WT-VLPs without adjuvants via
various immunization routes. After one week following immunization,
splenic lymphocytes were prepared and stimulated with FMP 58-66.
Cells were then stained for their surface expression of CD8 and
antigen-induced intracellular expression of IFN-γ. As shown in
Fig. 1A and B, both FMP-DE-VLPs and FMP-HI-VLPs signiﬁcantly
induced IFN-γ-producing CD8þ T cells in mice injected via any routes
tested without the need of adjuvants. By contrast, WT-VLPs without an
FMP 58-66 insert was not able to elicit IFN-γ-producing CD8þ T cells
(data not shown). Since i.p. injection was likely to generate high
frequencies (Fig. 1A and B), i.p. immunization was commonly used for
the following experiments.
We also performed comparative studies on the efﬁciency of
FMP-speciﬁc CTL induction between the SV40-VLP vaccination and
a conventional peptide vaccination (Fig. 1B). Mice were immu-
nized s.c. once with 50 μg of FMP 58-66 peptide in incomplete
Freund's adjuvant (IFA) or an equivalent amount of chimeric SV40-
VLPs harboring only 1.2 μg of FMP 58-66 peptide, followed by
intracellular IFN-γ staining. It was demonstrated that the fre-
quency of IFN-γ-secreting CD8þ T cells following the SV40-VLP
vaccination was signiﬁcantly higher than that following the pep-
tide vaccination (Fig. 1B). These data imply that the SV40-VLP
vaccination appeared to be superior to the conventional peptide
vaccination in terms of CTL induction.
Detection of the FMP-speciﬁc killing activity in the chimeric SV40-
VLPs-immunized mice
To address the FMP-speciﬁc cytotoxicity, 51Cr release assays
were carried out (Fig. 2A). Effector cells were prepared from
spleens of mice that had been immunized with WT-VLPs, FMP-
DE-VLPs or FMP-HI-VLPs in the absence of adjuvants. As shown in
Fig. 2A, FMP-speciﬁc killing responses were clearly detected in
FMP-DE-VLPs or FMP-HI-VLPs-immunized mice, but not in WT-
VLPs-injected mice (Fig. 2A). There was no signiﬁcant difference in
the induction of FMP-speciﬁc CTL activities between FMP-DE-VLPs
and FMP-HI-VLPs (Fig. 2A). To conﬁrm these results, we next
performed in vivo CTL assays. In accordance with the data in 51Cr
release assays (Fig. 2A), FMP-speciﬁc CTL activities were signiﬁ-
cantly observed in FMP-DE-VLPs- or FMP-HI-VLPs-immunized
mice (Fig. 2B) but not in WT-VLPs-immunized mice (data not
shown). These data demonstrate that both FMP-DE-VLPs and FMP-
HI-VLPs are efﬁcient to elicit CTLs that have the robust activity of
FMP 58-66-speciﬁc killing without the need of adjuvants.
Heterosubtypic protection against inﬂuenza A virus infection in the
chimeric SV40-VLPs-immunized mice
It was expected that FMP-speciﬁc CTLs induced by the chimeric
SV40-VLPs could preferentially kill inﬂuenza A virus-infected cells,
leading to the elimination of virus from the body. To verify this
assumption, mice were immunized with either WT-VLPs, FMP-DE-
VLPs or FMP-HI-VLPs without adjuvants, and then challenged
intranasally with 1102 TCID50 inﬂuenza virus A/PR8/34 (H1N1)
or A/Aichi/2/68 (H3N2). Firstly, we examined the body weight
change of mice challenged with inﬂuenza virus A/PR8/34. As
shown in Fig. 3A and B, mice immunized with FMP-DE-VLPs or
FMP-HI-VLPs did not change much their body weights after virus
challenge, whereas a signiﬁcant loss in body weight was observed
in the control mice inoculated with WT-VLPs (Fig. 3A and B).
Furthermore, virus titers in the lung were determined after 4 days
following the challenge with either inﬂuenza virus A/PR8/34
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Fig. 2. Detection of FMP 58-66-speciﬁc CTL killing activities by in vitro (A) and
in vivo (B) CTL assays. (A) HHD mice were immunized i.p. with either WT-VLPs
(square), FMP-DE-VLPs (circle) or FMP-HI-VLPs (triangle) without adjuvants. After
two weeks following immunization, spleen cells of the mice were stimulated twice
with peptide-pulsed syngeneic spleen cells. 51Cr-release assays were then per-
formed at various E:T ratios, using RMA–HHD cells pulsed with (black symbols) or
without (white symbols) FMP 58-66 as targets. Data are shown as the mean7SD.
Similar results were obtained in two independent experiments. Three mice per
group were used in each experiment. One-way ANOVA was performed for
comparison of data. n, Po0.01 compared to WT-VLPs; NS, not signiﬁcant between
FMP-DE-VLPs and FMP-HI-VLPs. (B) Spleen cells of naive HHD mice were pulsed
with FMP 58–66 and labeled with a high concentration (2.5 μM) of CFSE (H). As
a control, unpulsed spleen cells were labeled with a lower concentration (0.25 μM
of CFSE (L). A 1:1 mixture of each target cell population was injected i.v. into
immunized (imm.) and unimmunized (no imm.) mice. The numbers shown
indicate the percentage of antigen speciﬁc lysis. The data shown are representative
of three independent experiments.
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(H1N1) or A/Aichi/2/68 (H3N2). It was demonstrated that immu-
nization with FMP-DE-VLPs or FMP-HI-VLPs signiﬁcantly inhibited
the growth of both inﬂuenza PR8 and Aichi viruses in the lung
(Fig. 3C). These data strongly suggest that vaccination with either
FMP-DE-VLPs or FMP-HI-VLPs in the absence of adjuvants are
sufﬁciently capable of inducing heterosubtypic protection in mice
against inﬂuenza A infection presumably due to the substantial
accumulation of FMP 58-66-speciﬁc CTLs in the lung.
DNase I treatment of the chimeric SV40-VLPs did not disrupt the
induction of FMP-speciﬁc CTLs
During the puriﬁcation process of SV40-VLPs in the baculovirus
expression system, it was quite possible that baculoviral genome
was contaminated in the puriﬁed SV40-VLP fraction. The con-
taminated DNA might play an adjuvant-like role to trigger innate
immunity for the following acquired immunity. To exclude this
possibility, the FMP-DE-VLP and FMP-HI-VLP fractions were trea-
ted with DNase I prior to the inoculation of them into mice. After
immunization with DNase I-treated chimeric SV40-VLPs, spleen
cells were prepared from mice, and intracellular cytokine staining
assay and CTL assay were performed. As shown in Fig. 4, DNase I
treatment of the FMP-DE-VLP or FMP-HI-VLP fraction did not
disturb the induction of either IFN-γþ CD8þ T cells (Fig. 4A
and B) or FMP 58-66-speciﬁc CTLs (Fig. 4C) in mice. These results
suggest that the chimeric SV40-VLPs themselves may possess
intrinsic adjuvant-like properties. To discount the possible effect
of the contaminated genomic DNA, SV40-VLP fractions were
pretreated with DNase I in the following experiments.
To prove the self-adjuvant activity of SV40-VLPs, we investi-
gated the expression of maturation markers on the cell surface of
DCs exposed to SV40-VLPs. DCs of naive mice were incubated
in vitro with either WT-VLPs, FMP-DE-VLPs or FMP-HI-VLPs for
24 h, and the expression of CD80, CD86 and CD40 molecules,
WT-VLPs
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Fig. 3. Heterosubtypic protection against inﬂuenza A virus challenge. Mice were immunized with either WT-VLPs, FMP-DE-VLPs or FMP-HI-VLPs without adjuvants. After
one week following immunization, mice were challenged with either H1N1 (A/PR/8/34) virus (A–C) or H3N2 (A/Aichi/2/68) virus (C). (A and B) Mice were weighted daily,
and changes in body weight of mice were calculated as a percentage of the mean weight per group as compared with starting body weight. The data represent mean body
weights and SD of 5 mice per group. One-way ANOVA was performed for comparison of data between vaccination groups. n, Po0.05; nn, Po0.01, compared to mice
immunized with WT-VLPs. There was no signiﬁcant difference in body weight change between FMP-DE-VLPs-immunized mice (A) and FMP-HI-VLPs-immunized mice (B).
(C) After 4 days following viral challenge, viral titers in the lungs were determined by calculating TCID50 using MDCK cells. Each symbol represents an individual mouse and
horizontal bars represent the mean. One-way ANOVA was performed for comparison of data between vaccination groups. n, Po0.05; nn, Po0.01; NS, not signiﬁcant.
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which provide co-stimulatory signals for T cell activation, was
analyzed by ﬂow cytometry. However, any substantial upregula-
tion of these molecules was not observed in DCs pulsed with
either of them (data not shown).
Induction of FMP-speciﬁc memory CTLs in the chimeric SV40-VLPs-
immunized mice
We next examined whether long-lasting FMP-speciﬁc CTLs
could be elicited in the chimeric SV40-VLPs-immunized mice.
Mice were immunized once with either WT-VLPs, FMP-DE-VLPs
or FMP-HI-VLPs. After 30 days following the immunization, spleen
cells were prepared and stimulated in vitro with syngeneic spleen
cells pulsed with FMP 58-66. 51Cr-release assays were then
performed at various E:T ratios. FMP 58-66-speciﬁc CTLs were
detected in mice even on day 30 after immunization with the
chimeric SV40-VLPs (Fig. 5), but not in mice immunized with
WT-VLPs (data not shown). These data indicate that immunization
with the chimeric SV40-VLPs can efﬁciently generate long-lasting
memory CTLs in mice.
Discussion
It is well documented that papillomavirus L1-based VLPs are
able to induce potent humoral and cellular immune responses in
the absence of adjuvants (Greenstone et al., 1998; Liu et al., 2000;
Pejawar-Gaddy et al., 2010; Sadeyen et al., 2003), and therefore,
they are considered to be a promising vaccine vehicle in the
antigen delivery system. Because of the striking resemblance in
shape, polyomavirus VP1-based VLPs were also expected to
develop into a self-adjuvanting vaccine platform. However, several
reports have pointed out that they required the co-administra-
tion of an adjuvant for the induction of cell-mediated immunity
(Eriksson et al., 2011; Goldmann et al., 1999) although others have
taken the opposite view (Mazeike et al., 2012; Tegerstedt et al.,
2005). In the current study, we evaluated the potential of poly-
omavirus VLPs as a CTL-based vaccine platform using SV40. Our
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Fig. 4. Effect of DNase I treatment of the chimeric SV40-VLPs on the induction of FMP-speciﬁc CTLs. (A, B) Mice were immunized with FMP-DE-VLPs (A) or FMP-HI-VLPs
(B) that had been treated with (DNase I (þ)) or without (DNase I ()) DNase I. After one week, splenic lymphocytes were prepared, and stimulated with (þ) or without ()
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were treated with (triangle) or without (circle) DNase I and were inoculated into mice. After two weeks following immunization, spleen cells were stimulated twice with
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results have clearly revealed that the chimeric SV40-VLPs carrying
the FMP 58-66 epitope efﬁciently induced FMP-speciﬁc CTLs and
protective immunity against inﬂuenza A virus without the addi-
tion of adjuvants. As far as we know, this is the ﬁrst report
indicating that SV40-VLPs are able to serve as a CTL-based vaccine
platform with self-adjuvant properties.
It is possible to invoke several explanations for the discrepancy in
the requirement of adjuvants for CTL induction between SV40-VLPs
and other polyomavirus VLPs (Eriksson et al., 2011; Goldmann et al.,
1999). The key to the solution may be that the plasma membrane
receptor for SV40 is different from those for other polyomaviruses
(Ewers et al., 2010; Tsai et al., 2003). The model we favor is that the
signal transduction pathway associated with the stimulation of SV40-
VLPs may activate innate immunity more vigorously than others by
an unknown mechanism. It is also possible to assume that chimeric
SV40-VLPs carrying an epitope may be more efﬁciently internalized,
processed and cross-presented by APCs such as DCs than other
polyomavirus VLPs. If this is the case, several other polyomavirus
VLPs may require the addition of adjuvants to improve their immune
responses. These two hypotheses are not mutually exclusive, and
both may occur simultaneously. Alternatively, the immunogenicity of
inserted epitopes may account for the difference in the adjuvant
requirement.
Papillomavirus VLPs were demonstrated to strongly elicit
phenotypic maturation of DCs in vitro by upregulating maturation
markers such as CD80, CD86, and CD40 (Lenz et al., 2001). The
level of DC maturation was as high as that after exposure to a
positive control, bacterial LPS (Lenz et al., 2001). On the contrary,
several groups have shown that human (Lenz et al., 2001) or
murine (Boura et al., 2005; Tegerstedt et al., 2007) polyomavirus
VLPs did not induce phenotypic DC maturation in vitro at all in the
similar experiments although they were internalized into cells. In
agreement with these results, we also found that SV40-VLPs failed
to induce upregulation of maturation markers on the surface of
DCs (data not shown). In contrast to the in vitro experiments
mentioned above, we (Figs. 1–3) and others (Mazeike et al., 2012;
Tegerstedt et al., 2005) have shown that the in vivo immunization
with polyomavirus VLPs generated potent CTL responses and
protective immunity against viral infection and tumors. Boura
et al. (2005) attempted to explain the difference in behavior
between in vivo and in vitro treated cells with an alternative
cross-presentation mechanism described by Neijssen et al. (2005).
In this paper, it was demonstrated that peptides generated by
proteasomal degradation could be transferred directly from the
cytoplasm of one cell into the cytoplasm of its neighbor through
gap junctions. Alternatively, a novel pathway of indirect antigen
presentation, referred to as cross-dressing (Wakim and Bevan,
2011), may also be able to account for this issue, whereby an
uninfected APC acquires pre-existing MHC class I/peptide complex
molecules from a virus-infected cell. Taken together, it may be
possible to explain that the gap-junction-mediated intracellular
peptide coupling and/or the cross-dressing may play an important
role in the in vivo induction of strong cellular immunity after
immunization with the SV40-VLP vaccine platform although
further experiments are required.
SV40 was discovered as a contaminated material in the polio
vaccine (Butel and Lednicky, 1999; Hilleman, 1998), and hundreds
of millions of people have been unknowingly exposed to it during
immunization with polio vaccine. Fortunately, there is no evidence
so far that SV40 is harmful to human who received polio vaccine.
It appears unlikely that SV40 infection alone is sufﬁcient to cause
human malignancy but it seems possible that SV40 may act as a
cofactor in the pathogenesis of some tumors (Qi et al., 2011).
However, it is considered to be safe for humans to use SV40-VLPs
as a vaccine material because there is no evidence that SV40 VP1
protein has acute or chronic cytotoxicity against human cells. In
general, multiple immunizations are required for effective vac-
cines. Similar to other VLPs and viral vectors, however, SV40-VLPs
may potentially limit the effectiveness of multiple administrations
due to the induction of anti-SV40-VLP immunity including neu-
tralizing antibodies. Although we showed that the SV40-VLP
vaccine was superior to the synthetic peptide vaccine in the
efﬁciency of CTL induction (Fig. 1B), multiple injections could
allow the peptide vaccine to improve the efﬁciency. In addition,
people who received the polio vaccine produced around 1960
were potentially sensitized with SV40 because SV40 had been
contaminated in the polio vaccine (Butel and Lednicky, 1999;
Hilleman, 1998). However, it was shown that the mucosal immu-
nization with a recombinant vaccinia virus expressing HIV gp160
induced strong HIV-speciﬁc CTL responses even in mice preimmu-
nized with wild type vaccine virus (Belyakov et al., 1999). There-
fore, the mucosal vaccination may overcome the barrier caused by
pre-existing immunity against SV40-VLPs. It should be noted that
i.n. mucosal immunization was sufﬁcient to induce detectable IFN-
γ-producing CD8þ T cell production in the current study (Fig. 1A
and B). Furthermore, immunization with SV40-VLP-pulsed APCs
may enable repeated application because it was reported that
immunization with adenoviral vector-infected cells elicited strong
cellular immune responses speciﬁc for an inserted antigen but
induced very weak anti-adenovirus antibodies (Sun et al., 2012).
The heterologous prime-boost immunization may also be able to
circumvent this problem (Amara et al., 2001).
In the current study, we demonstrated the data of SV40-VLPs
with only a single epitope, FMP 58-66. We also know that SV40-
VLPs carrying a tumor-related epitope derived from Wilms' tumor
protein, WT1 (Oka et al., 2008) could induce WT1-speciﬁc CTLs in
mice (unpublished data), suggesting that our VLP system could be
applied to a broad range of epitopes. However, it should be
difﬁcult to make a single chimeric SV40-VLP carrying many
different kinds of epitopes inserted into the DE or HI loop. The
epitope approach to vaccine development offers several potential
advantages. For example, synthetic peptides are relatively safer
than antigenic proteins of origin. However, the large degree of HLA
polymorphism is a major obstacle in the development of epitope-
based vaccines. Moreover, broad T-cell immune responses that
are directed against multiple epitopes are desirable because
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Fig. 5. Induction of long-lasting memory CTLs. HHD mice were immunized once
with FMP-DE-VLPs or FMP-HI-VLPs. At day 30 after the immunization, spleen cells
were prepared, and stimulated in vitro twice with peptide-pulsed syngeneic spleen
cells. 51Cr-release assays were then carried out at various E:T ratios, using RMA–
HHD cells (circle) and RMA cells (triangle) pulsed with (black symbols) or without
(white symbols) FMP 58-66 as targets. Data are shown as the mean7SD. Six mice
per group were used in the experiments. n, Po0.01; nn, Po0.05 compared to RMA–
HHD cells pulsed without FMP 58-66.
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viruses are less likely to accumulate escape mutations under broad
immune responses. We previously showed that SV40-VLPs could
encapsulate heterologous proteins fused to the C-terminus of
minor capsid proteins VP2/3, and deliver them into mammalian
cells (Inoue et al., 2008). Therefore, it is possible to make SV40-
VLPs that accommodate an antigenic protein containing multiple
epitopes associated with a variety of HLA class I molecules.
In conclusion, we have shown that the chimeric SV40-VLPs
harboring the FMP 58-66 epitope could effectively induced
inﬂuenza-speciﬁc CTLs and protective immunity against inﬂuenza
virus infection without the need of adjuvants. Because DNase I
treatment of the chimeric SV40-VLPs did not disrupt the induction
of CTLs, the intrinsic adjuvant property of the chimeras may result
from VLP structural elements and not from DNA contaminants in
the VLP preparation. Thus, these data may offer strong evidence
that the chimeric SV40-VLPs harboring a CTL epitope is a promis-
ing CTL-based vaccine platform with self-adjuvant properties.
Materials and methods
Synthetic peptide
A synthetic peptide corresponding to the HLA-A⁎02:01-
restricted FMP 58-66 epitope (sequence: GILGFVFTL) (Gotch
et al., 1987) was synthesized by Operon Biotechnologies (Tokyo,
Japan).
Mice
Mice express a transgenic HLA-A⁎02:01 monochain, designated
as HHD, in which human β2-microglobuin (β2m) is covalently
linked to a chimeric heavy chain composed of HLA-A⁎02:01 (α1
and α2 domains) and H-2Db (α3, transmembrane, and cytoplasmic
domains) (Pascolo et al., 1997). Eight- to twelve-week-old mice
were used for all experiments. Mice were housed in appropriate
animal care facilities at Saitama Medical University, and were
handled according to the international guideline for experiments
with animals. Experiments in the present study were approved by
the Animal Research Committee of Saitama Medical University.
Cell lines
RMA–HHD (Pascolo et al., 1997) is a mouse lymphoma cell line,
RMA transfected with the HHD gene. RMA–HHD cells were
maintained in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO)
supplemented with 10% fetal calf serum (FCS) (JRH Biosciences,
Lenexa, KS) (R-10) containing 500 μg/ml G418 (Sigma-Aldrich).
The parental cell line, RMA was cultured in R-10. Madin-Darby
canine kidney (MDCK) cell line was obtained from the American
Type Culture Collection (ATCC) (Rockville, MD), and was main-
tained in Dulbecco's Modiﬁed Eagle's Medium (Sigma-Aldrich)
supplemented with 10% FCS. Sf9 insect cells (Invitrogen, Carlsbad,
CA) were cultured in supplemented Sf-900 II medium (Invitrogen)
containing 10% FCS.
Generation of the chimeric SV40-VLPs
Chimeric SV40-VP1 genes containing a nucleotide sequence
encoding the FMP 58-66 epitope were constructed by the over-
hanging PCR method as described previously (Takahashi et al.,
2008). In brief, six nucleotides corresponding to the amino acid
residues 137-138 in the DE loop or 273-274 in the HI loop of SV40
VP1 were replaced by a 45-nucleotide insertion encoding the 15
amino-acid-long peptide (GGG-GILGFVFTL-GGG) which is the FMP
58-66 epitope ﬂanked by three tandem glycine spacers at both the
N- and C-terminal ends. The PCR-ampliﬁed, chimeric SV40-VP1
genes were cloned into the pFastBac1 plasmid vector (Invitrogen),
and the cloned pFastBac1 was transformed in DH10Bac (Invitro-
gen) competent cells which hold a baculovirus shuttle vector,
bacmid. The recombinant bacmid DNA was then isolated and
transfected into Sf9 insect cells using the transfection reagent,
Lipofectin (Invitrogen), resulting in the production of recombinant
baculovirus expressing the chimeric SV40-VP1. The culture med-
ium containing virus was collected at 3 days after transfection,
centrifuged to remove cells and cell debris, and stored as a viral
stock. The viral titer in the stock was determined by the standard
plaque assay using Sf9 cells.
To prepare the chimeric SV40-VLPs carrying the FMP 58-66
epitope in the DE loop (FMP-DE-VLPs) or HI loop (FMP-HI-VLPs),
Sf9 cells were infected with the recombinant baculovirus in the
stock, and incubated in TC-100 medium (AppliChem Inc., St. Louis,
MO) containing 10% FCS and tryptose phosphate broth at 27 1C for
3 days. Sf9 cells were then harvested, washed, and resuspended in
a buffer containing 20 mM Tris–HCl (pH 7.9) and 1% deoxycholic
acid. After sonication, the cell lysate was centrifuged and the pellet
was resuspended in the Optiprep buffer containing 20 mM Tris–
HCl (pH 7.9) and 50% Optiprep (Axis-Shield plc, Dundee, Scotland).
The presence of SV40-VLPs in the solution was conﬁrmed under an
electron microscope using H-7500 (Hitachi, Tokyo, Japan). It was
found that the chimeric SV40-VLPs retained spherical structures of
40–45 nm in diameter. In some experiments, the Optiprep solution
containing 2.5 μg SV40-VLPs was treated with 0.33 U of DNase I
(Worthington, Lakewood, NJ) at 37 1C for 1 h. Endotoxin levels in
the preparations were determined to be below the detection limit
(i.e.o0.06 EU/ml) by PYROGENT Plus (Lonza, Walkersville, MD)
Immunization
Mice were immunized once with 50 μg/mouse of the chimeric
SV40-VLPs or wild-type SV40-VLPs (WT-VLPs) in 100 μl of the
Optiprep buffer via various immunization routes, including sub-
cutaneous (s.c.), intraperitoneal (i.p.), and intramuscular (i.m.)
administrations without a booster immunization. For intranasal
(i.n.) immunization, mice were anesthetized by an intraperitoneal
injection of ketamine (175 mg/g weight) (Sigma-Aldrich) and
xylazine (3.5 mg/g weight) (Bayer Holding Ltd., Tokyo, Japan),
and inoculated intranasally once with 40 μl/mouse of solution
containing 20 μg of SV40-VLPs. Peptide immunizations were
performed by one-shot s.c. injection at the base of the tail with
50 μg/mouse of FMP 58-66 in 100 μl of IFA (Sigma-Aldrich) as
previously described (Schell et al., 2001).
Intracellular cytokine staining
Intracellular cytokine staining was performed as described
previously (Matsui et al., 2005). Brieﬂy, after one week following
immunization, 2106 spleen cells of mice were incubated with
10 μM of FMP 58-66 for 5 h at 37 1C in the presence of brefeldin A
(GoldiPlug™, BD Biosciences, San Jose, CA). After Fc receptors were
blocked with the rat anti-mouse CD16/CD32 mAb (Fc Block™, BD
Biosciences), cells were stained with ﬂuorescein isothiocyanate
(FITC)-conjugated rat anti-mouse CD8α monoclonal antibody
(mAb) (BD Biosciences) for 30 min at 4 1C. The cells were then
ﬁxed, permeabilized, and stained with phycoerythrin (PE)-con-
jugated rat anti-mouse interferon-gamma (IFN-γ) mAb (BD Bio-
sciences). After the cells were washed, ﬂow cytometric analyses
were performed.
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In vivo CTL assay
In vivo CTL assay was carried out as described previously
(Matsui et al., 2010). Brieﬂy, spleen cells from naive HHD mice
were split into two populations. One population was pulsed with
10 μM of FMP 58-66 and labeled with a high concentration
(2.5 μM) of carboxyﬂuorescein diacetate succinimidyl ester (CFSE)
(Molecular Probes, Eugene, OR), and the other population was
unpulsed and labeled with a lower concentration (0.25 μM) of
CFSE. An equal number (1107) of cells from each population was
adoptively transferred into mice that had been immunized with
the chimeric SV40-VLPs one week earlier. Twelve hours later,
spleen cells were prepared and analyzed by ﬂow cytometry. To
calculate speciﬁc lysis, the following formula was used: % speciﬁc
lysis¼(1{(number of CFSElow cells in normal mice)/(number
of CFSEhigh cells in normal mice)}/{(number of CFSElow cells in
immunized mice)/(number of CFSEhigh cells in immunized
mice)}100.
51Cr-release assay
51Cr-release assays were carried out as described before
(Matsui et al., 2005). In brief, after two weeks following immuni-
zation, spleen cells of the immunized mice were stimulated twice
with gamma-irradiated, syngeneic spleen cells pulsed with 10 μM
of FMP 58-66 after one-week interval, and were used as effector
cells. For the detection of memory CTLs, spleen cells were
prepared on day 30 after the immunization, and stimulated twice
with FMP 58-66 as described above. In the second peptide
stimulation, human recombinant interleukin-2 (Cetus, Berkeley,
CA) was added at a ﬁnal concentration of 200 units/ml into the
culture medium. RMA–HHD cells pulsed with or without 10 μM of
FMP 58-66 were labeled with 100 μCi of Na251CrO4 as target cells.
After a 4-h incubation, supernatant of each well was harvested and
the radioactivity was counted. Results were calculated as the
means of triplicate assays. Percent speciﬁc lysis was calculated
according to the formula: speciﬁc lysis¼[(cpmsample
cpmspontaneous)/(cpmmaximumcpmspontaneous)]100. Spontaneous
release represents the radioactivity released by target cells in the
absence of effectors, and maximum release represents the radio-
activity released by target cells lysed with 5% Triton X-100.
Inﬂuenza A virus
Two inﬂuenza A virus strains, H1N1 (A/PR8/34) and H3N2 (A/
Aichi/2/68) were propagated in 10-day-old embryonated hen's
eggs at 35 1C for 3 days. Egg allantoic ﬂuid containing virus was
then harvested and stocked at 80 1C. Virus titers were deter-
mined by calculating the 50% tissue culture infectious dose
(TCID50) using MDCK cells (Suda et al., 2011). H1N1 (A/PR/8/34)
virus was purchased from ATCC, and H3N2 (A/Aichi/2/68) virus
was kindly provided by Dr. H. Kida at Hokkaido University, Japan.
Viral challenge
After one week following immunization, mice were anesthe-
tized by an i.p. injection of ketamine (Sigma-Aldrich) and xylazine
(Bayer Holding Ltd.), and were challenged i.n. with 1102 TCID50
of either H1N1 (A/PR/8/34) virus or H3N2 (A/Aichi/2/68) virus
resuspended in 40 μl of PBS per animal. Mice were weighted daily
for two weeks. For virus titration, mice were sacriﬁced on day
4 after the virus challenge, and virus titers in their lungs were
determined by calculating TCID50 using MDCK cells as described
previously (Suda et al., 2011).
Detection of maturation markers on the surface of DCs
DCs were generated from mouse bone marrow cells as
described (Lutz et al., 1999; Matsui et al., 2002). To investigate
maturation, 5105 DCs of naive HHD mice were resuspended in
200 μl of R-10, and were incubated with 2.5 μg of DNase I-treated
FMP-DE-VLPs, FMP-HI-VLPs, or WT-VLPs for 24 h at 371C in each
well of a round-bottomed 96-well plate. Cells were stained with
FITC-conjugated rat anti-mouse CD80, CD86 or CD40 mAb (BD
Biosciences) for 30 min at 4 1C, and were analyzed by ﬂow
cytometry.
Statistical analyses
Statistical analyses between two groups were performed with
Student's t-test. One-way ANOVA followed by post hoc tests were
carried out for statistical analyses between multiple groups using
GraphPad Prism 5 software. A value of Po0.05 was considered
statistically signiﬁcant.
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